Amanda Lee Garner

Amanda Lee Garner

Auto-generated profile, based on publicly available information

Amanda Lee Garner

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AGAmanda L. Garner
Amanda L. Garner

16 May 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
DLDaniel A. Lorenz
Daniel A. Lorenz
TKTanpreet Kaur
Tanpreet Kaur
SKSamuel A. Kerk
Samuel A. Kerk
EGErin E. Gallagher
Erin E. Gallagher
JSJorge Sandoval
Jorge Sandoval
AGAmanda L. Garner
Amanda L. Garner
Dysregulation of microRNA (miRNA) expression has been linked to many human diseases; however, because of the challenges associated with RNA-targeted drug discovery, additional approaches are needed for probing miRNA biology. The emerging regulatory role of miRNA-binding proteins in miRNA maturation presents such an alternative strategy. Exploiting our laboratory’s click chemistry-based high-throughput screening (HTS) technology, catalytic enzyme-linked click chemistry assay or cat-ELCCA, we have designed a modular method by which to discover new chemical tools for manipulating pre-miRNA–miRNA–binding protein interactions. Using the pre-let-7d–Lin28 interaction as proof-of-concept, the results presented demonstrate how HTS using cat-ELCCA can enable the discovery of small molecules targeting RNA–protein interactions.

1 November 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ESEmily J. Sherman
Emily J. Sherman
DMDylan C. Mitchell
Dylan C. Mitchell
AGAmanda L. Garner
Amanda L. Garner
MicroRNAs (miRNAs or miRs) are small, noncoding RNAs that are implicated in the regulation of most biological processes. Global miRNA biogenesis is altered in many cancers, and RNA-binding proteins play a role in miRNA biogenesis, presenting a promising avenue for targeting miRNA dysregulation in diseases. miR-34a exhibits tumor-suppressive activities by targeting cell cycle regulators CDK4/6 and anti-apoptotic factor BCL-2, among other regulatory pathways such as Wnt, TGF-β, and Notch signaling. Many cancers exhibit down-regulation or loss of miR-34a, and synthetic miR-34a supplementation has been shown to inhibit tumor growth in vivo. However, the post-transcriptional mechanisms that cause miR-34a loss in cancer are not entirely understood. Here, using a proteomics-mediated approach in non-small-cell lung cancer (NSCLC) cells, we identified squamous cell carcinoma antigen recognized by T-cells 3 (SART3) as a putative pre-miR-34a–binding protein. SART3 is a spliceosome recycling factor and nuclear RNA-binding protein with no previously reported role in miRNA regulation. We found that SART3 binds pre-miR-34a with higher specificity than pre-let-7d (used as a negative control) and elucidated a new functional role for SART3 in NSCLC cells. SART3 overexpression increased miR-34a levels, down-regulated the miR-34a target genes CDK4/6, and caused a cell cycle arrest in the G1 phase. In vitro binding experiments revealed that the RNA-recognition motifs within the SART3 sequence are responsible for selective pre-miR-34a binding. Our results provide evidence for a significant role of SART3 in miR-34a biogenesis and cell cycle progression in NSCLC cells.

1 March 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKTanpreet Kaur
Tanpreet Kaur
AMArya Menon
Arya Menon
AGAmanda L. Garner
Amanda L. Garner

1 January 2018 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
DLDaniel A. Lorenz
Daniel A. Lorenz
SRSteve Vander Roest
Steve Vander Roest
MLMartha J. Larsen
Martha J. Larsen
AGAmanda L. Garner
Amanda L. Garner
MicroRNAs (miRNAs) are small gene regulatory RNAs, and their expression has been found to be dysregulated in a number of human diseases. To facilitate the discovery of small molecules capable of selectively modulating the activity of a specific miRNA, we have utilized new high-throughput screening technology targeting Dicer-mediated pre-miRNA maturation. Pilot screening of ~50,000 small molecules and ~33,000 natural product extract libraries against pre-miR-21 processing indicated the potential of our assay for this goal, yielding a campaign Z′ factor of 0.52 and an average plate signal-to-background (S/B) ratio of 13. Using two-dimensional screening against a second pre-miRNA, pre-let-7d, we evaluated the selectivity of confirmed hits. The results presented demonstrate how high-throughput screening can be used to identify selective small molecules for a target RNA.

17 December 2014 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
DLDaniel A. Lorenz
Daniel A. Lorenz
JSJames M. Song
James M. Song
AGAmanda L. Garner
Amanda L. Garner